HomeProductsBuilding BlocksHeterocyclic ScaffoldsTetrahydrofuransBlarcamesine
Chemical structure of CAS 195615-83-9

Blarcamesine

In Stock•Starting at $128 for 25 mg•Purity ≥ 98%
CAS No.195615-83-9
MDL No.N/A
MFC19H23NO
MW281.40
InChI KeyBOTHKNZTGGXFEQ-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
25 mg98%$128In Stock
50 mg98%$215In Stock
100 mg98%$363In Stock
250 mg98%$685In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.195615-83-9
Product NameBlarcamesine

Associated Conditions

Alzheimer disease·Rett syndrome·Parkinson disease
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

ANAVEX®2-73 (blarcamesine), a Sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of Rett syndrome.

Pharmacology, biochemistry, and behavior • Vol. 187 • 2019
PMID: 31704481DOI: 10.1016/j.pbb.2019.172796

Protection by sigma-1 receptor agonists is synergic with donepezil, but not with memantine, in a mouse model of amyloid-induced memory impairments.

Behavioural brain research • Vol. 296 • 2016
PMID: 26386305DOI: 10.1016/j.bbr.2015.09.020

Mitochondrial protection by the mixed muscarinic/σ1 ligand ANAVEX2-73, a tetrahydrofuran derivative, in Aβ25-35 peptide-injected mice, a nontransgenic Alzheimer's disease model.

Frontiers in cellular neuroscience • Vol. 8 • 2014
PMID: 25653589PMC: PMC4299448DOI: 10.3389/fncel.2014.00463

Blockade of Tau hyperphosphorylation and Aβ₁₋₄₂ generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ₁ receptor agonist, in a nontransgenic mouse model of Alzheimer's disease.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology • Vol. 38, Issue 9 • 2013
PMID: 23493042PMC: PMC3717544DOI: 10.1038/npp.2013.70

Documentation

Similar Products